 |
 |
Synta Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, and commercializing novel pharmaceutical products for extending and
enhancing the lives of patients with severe medical conditions, including
cancer and chronic inflammatory disease. Synta has a unique chemical compound
library, an integrated discovery engine, and a diverse pipeline of clinical-
and preclinical-stage drug candidates with distinct mechanisms of action and
novel chemical structures. All clinical candidates were invented internally by
Synta scientists using our compound library and discovery capabilities.
Synta: big pharma assets, small pharma speed
-
Diverse pipeline of novel, small-molecule compounds targeting multiple
therapeutic areas: Each of our drug candidates represents novel
compounds with distinct mechanisms of action targeting areas of high unmet
medical need. Many of our programs include multiple drug candidates, e.g., our
first-generation Hsp90 inhibitor STA-9090 and a second-generation orally
bioaviable compound, and target a broad number of indications within cancer and
autoimmune/inflammatory diseases.
-
Productive discovery engine and chemistry platform: Our unique chemical
compound library – proprietary compounds collected over two decades from
industrial and academic sources not typically found at pharmaceutical firms –
combined with our high throughput screening and in vivo modeling capabilities;
our medicinal, computational, analytic, and process-development chemistry
expertise; and our in vitro and in vivo toxicology and DMPK experience allow us
to continue to generate promising new drug candidates each year.
-
Strong financial and strategic position: Our cash position and the
benefits of having one partnered and four unpartnered programs provides the
flexibility of multiple options for choosing when, with whom, and under what
type of structure to partner with larger pharmaceutical companies.
-
Strong intellectual property position: We have an extensive intellectual
property portfolio consisting of over 700 issued or pending patents. All Synta
compounds currently in clinical trials represent novel chemical structures
protected by issued or allowed composition of matter patents, as well as a
robust package of related structure, mechanism, formulation, manufacturing, and
administration patents.
-
Experienced management team: The Synta management team has experience in
all stages of drug discovery, development and commercialization. In addition to
developing our current pipeline from discovery through Phase 3, including
initiating and overseeing over three dozen clinical trials, the Synta
management team has collectively been involved in the pre-clinical development,
clinical development, and commercial launch of multiple leading drugs.
Synta combines the high-energy culture and exciting growth opportunities of a
new biotechnology company with the drug development assets and expertise of a
mature pharmaceutical organization.
Click here to view
the Corporate Fact Sheet.
|
 |
